Longitudinal multi-trajectory phenotypes of severe eosinophilic asthma on type 2 biologics treatment.

ABSTRACT:

Background

Limited understanding exists regarding the progression trajectory of severe eosinophilic asthma (SEA) patients on type 2 biologics therapies.

Objective

We aim to explore distinct longitudinal phenotypes of these patients based on crucial asthma biomarkers.

Methods

We enrolled 101 adult patients with SEA. Of these, 51 were treated with anti-IL5/IL5Rα or anti-IL5/IL5RαR antibody, and 50 with anti-IL-4Rα antibody. Multi-trajectory analysis, an extension of univariate group-based trajectory modeling, was used to categorize patients based on their trajectories of forced expiratory volume in 1 s (FEV₁), blood eosinophil counts (BEC), and fractional exhaled nitric oxide (FeNO) levels at baseline, and after 1, 6, and 12 months of treatment. Associations

SUBMITTER: Pham DD 

PROVIDER: S-EPMC11617764 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature